Krishna Institute of Medical Sciences Limited (IN:KIMS)
:KIMS
Want to see IN:KIMS full AI Analyst Report?
Top Page
Krishna Institute of Medical Sciences Limited
(KIMS)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹784.00
▲(20.06% Upside)
Action:Reiterated
Date:05/17/26
The score is mainly constrained by weakening profitability, rising leverage, and deeply negative free cash flow despite strong revenue growth. Technicals are supportive with a clear uptrend, but valuation is a significant headwind due to the very high P/E.
Positive Factors
Sustained revenue growth
Consistent multi-year revenue growth (about 3x from 2021–2026 and mid-teens growth in 2026) indicates expanding patient volumes and deeper market penetration. This durable top-line momentum supports scale economics, higher capacity utilization and the potential for margin recovery if cost controls follow.
Negative Factors
Sharply rising leverage
Debt‑to‑equity rising to ~1.89 increases interest and refinancing exposure and reduces strategic flexibility. Heavy debt funding for expansion amplifies downside risk if earnings don’t scale as expected, limiting ability to absorb shocks or invest opportunistically over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Consistent multi-year revenue growth (about 3x from 2021–2026 and mid-teens growth in 2026) indicates expanding patient volumes and deeper market penetration. This durable top-line momentum supports scale economics, higher capacity utilization and the potential for margin recovery if cost controls follow.
Read all positive factors
Krishna Institute of Medical Sciences Limited (KIMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹302.26B
Dividend YieldN/A
Average Volume (3M)23.04K
Price to Earnings (P/E)103.1
Beta (1Y)0.76
Revenue Growth28.65%
EPS Growth-37.24%
CountryIN
Employees5,013
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)8.39
Shares Outstanding400,138,950
10 Day Avg. Volume26,167
30 Day Avg. Volume23,042
Financial Highlights & Ratios
PEG Ratio-2.77
Price to Book (P/B)11.07
Price to Sales (P/S)6.37
P/FCF Ratio-22.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.18
Revenue Forecast (FY)₹50.20B
Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model
Company Description
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reprod...
How the Company Makes Money
KIMS primarily earns revenue by delivering hospital-based healthcare services across its facilities. Key revenue streams typically include: (1) Inpatient services: charges for admissions, room/bed occupancy, nursing care, intensive/critical care, ...
Krishna Institute of Medical Sciences Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
48
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70B | 39.05B | 30.04B | 24.74B | 21.68B | 16.51B |
| Gross Profit | 20.12B | 21.31B | 18.77B | 15.21B | 13.41B | 10.34B |
| EBITDA | 8.24B | 8.02B | 8.24B | 6.52B | 6.43B | 5.46B |
| Net Income | 3.36B | 2.41B | 3.85B | 3.10B | 3.36B | 3.33B |
Balance Sheet | ||||||
| Total Assets | 66.25B | 77.59B | 57.36B | 38.52B | 29.41B | 19.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 898.00M | 1.02B | 1.32B | 1.34B | 1.90B |
| Total Debt | 31.87B | 42.53B | 25.57B | 13.55B | 6.78B | 2.57B |
| Total Liabilities | 40.49B | 52.00B | 33.17B | 17.59B | 10.03B | 4.97B |
| Stockholders Equity | 22.70B | 22.47B | 21.38B | 18.28B | 16.70B | 13.87B |
Cash Flow | ||||||
| Free Cash Flow | -4.69B | -11.15B | -4.27B | -1.26B | -1.42B | 1.54B |
| Operating Cash Flow | 2.85B | 3.13B | 5.82B | 5.21B | 4.32B | 3.24B |
| Investing Cash Flow | -7.17B | -15.69B | -11.16B | -7.53B | -5.47B | -4.12B |
| Financing Cash Flow | 4.57B | 12.55B | 5.43B | 2.17B | 196.42M | 609.99M |
Krishna Institute of Medical Sciences Limited Technical Analysis
Positive
653.00
Price Trends
680.85
Positive
663.85
Positive
689.71
Positive
Market Momentum
24.71
Negative
62.55
Neutral
59.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Positive. The current price of 653 is below the 20-day moving average (MA) of 714.37, below the 50-day MA of 680.85, and below the 200-day MA of 689.71, indicating a bullish trend. The MACD of 24.71 indicates Negative momentum. The RSI at 62.55 is Neutral, neither overbought nor oversold. The STOCH value of 59.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KIMS.
Krishna Institute of Medical Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹388.91B | 75.82 | ― | 0.24% | 25.81% | -0.76% | |
66 Neutral | ₹1.16T | 54.94 | ― | 0.27% | 15.76% | 34.29% | |
66 Neutral | ₹333.70B | 46.41 | ― | 0.04% | 19.44% | 15.55% | |
61 Neutral | ₹735.33B | 86.12 | ― | 0.11% | 15.99% | 24.81% | |
61 Neutral | ₹1.05T | 84.46 | ― | 0.14% | 24.44% | 40.69% | |
56 Neutral | ₹302.26B | 103.07 | ― | ― | 28.65% | -37.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KIMS
Krishna Institute of Medical Sciences Limited
769.80
101.65
15.21%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,304.10
1,367.66
19.72%
IN:FORTIS
Fortis Healthcare Ltd.
967.05
243.81
33.71%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,091.55
-56.57
-4.93%
IN:MEDANTA
Global Health Limited
1,239.80
55.83
4.72%
IN:NH
Narayana Hrudayalaya Ltd.
1,928.70
208.45
12.12%
Krishna Institute of Medical Sciences Limited Corporate Events
KIMS Confirms SEBI-Compliant Dematerialisation of Shares for Q4 FY26
Apr 12, 2026
Krishna Institute of Medical Sciences Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026, as confirmed by its registrar and share ...
KIMS Closes Trading Window Ahead of FY26 Audited Results
Mar 26, 2026
Krishna Institute of Medical Sciences Limited has announced the closure of its trading window from 1 April 2026 until 48 hours after it declares its audited standalone and consolidated financial results for the quarter and year ending 31 March 202...
KIMS Publishes Postal Ballot Notice, Confirms E-Voting and Dispatch Compliance
Mar 17, 2026
Krishna Institute of Medical Sciences Limited has notified the stock exchanges that it has published a postal ballot notice in two newspapers, Financial Express in English and Navatelangana in Telugu, as required under Indian company law and SEBI ...
KIMS Board Clears Plan to Raise Up to ₹1,500 Crore via Equity Issuance
Mar 11, 2026
Krishna Institute of Medical Sciences Limited, a leading Indian hospital chain, has approved a significant capital-raising plan to support its growth and operational needs. The company’s board has cleared a proposal to issue equity shares, p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.